ViCentra Closes USD 74M Series C Funding
- ViCentra, the Utrecht, Netherlands-based company behind Kaleido, a small and light wearable insulin pump (“patch pump”), closed a EUR 65m (USD 74m) Series C financing
- The round was led by new investor Partners in Equity BV, the Amsterdam based Venture Capital firm with a long-term focus, with participation from existing investors
- The company intends to use the funds to expand operations and further accelerate its commercial rollout, scale its manufacturing operations and prepare for FDA filing
- The commercial launch of the Kaleido system will focus on the Netherlands, France, Germany and the UK, with additional regions targeted in due course
- The company develops, manufactures and markets next generation insulin pumps and other products to treat people with diabetes
